Cells derived from iPSC can be immunogenic -- Yes or No

The induced pluripotent stem cells （iPSCs）, derived by ectopic expression of reprogramming factors in somatic cells, can potentially provide unlimited autologous cells for regenerative medicine. In theory, the autologous cells derived from patient iPSCs should be immune tolerant by the host without...

Full description

Saved in:
Bibliographic Details
Published inProtein & cell Vol. 5; no. 1; pp. 1 - 3
Main Authors Cao, Jiani, Li, Xiaoyan, Lu, Xiao, Zhang, Chao, Yu, Honghao, Zhao, Tongbiao
Format Journal Article
LanguageEnglish
Published Beijing Higher Education Press 2014
Subjects
Animals
Biochemistry
Biomedical and Life Sciences
Cell Biology
Cell Cycle Proteins - metabolism
Cell Transplantation - methods
Developmental Biology
Discussion
Graft Rejection - immunology
Human Genetics
Induced Pluripotent Stem Cells - immunology
Induced Pluripotent Stem Cells - transplantation
iPS
Life Sciences
Membrane Proteins - metabolism
Mice, Knockout
Protein Science
Stem Cells
Teratoma - immunology
Teratoma - metabolism
体细胞
免疫原性
免疫排斥反应
免疫耐受
再生医学
多能干细胞
细胞分化
Immune Rejection
Pluripotent Stem Cell
Teratoma
Autologous Cell
iPSC
Online AccessGet full text

Cover

More Information
Summary:The induced pluripotent stem cells （iPSCs）, derived by ectopic expression of reprogramming factors in somatic cells, can potentially provide unlimited autologous cells for regenerative medicine. In theory, the autologous cells derived from patient iPSCs should be immune tolerant by the host without any immune rejections. However, our recent studies have found that even syn- geneic iPSC-derived cells can be immunogenic in syn- geneic hosts by using a teratoma transplantation model （Nature 474：212-215, 2011）. Recently two research groups differentiated the iPSCs into different germ lay- ers or cells, transplanted those cells to the syngeneic hosts, and evaluated the immunogenicity of those cells. Both of the two studies support our conclusions that some certain but not all tissues derived from iPSCs can be immunogenic, although they claimed either ＂negli- gible＂ or ＂lack of＂ immunogenicity in iPSC derivatives （Nature 494：100-104, 2013; Cell Stem Cell 12：407-412, 2013）. To test the immunogenicity of clinically valuable cells differentiated from human iPSCs are emergenUy required for translation of iPSC technology to clinics.
Bibliography:The induced pluripotent stem cells （iPSCs）, derived by ectopic expression of reprogramming factors in somatic cells, can potentially provide unlimited autologous cells for regenerative medicine. In theory, the autologous cells derived from patient iPSCs should be immune tolerant by the host without any immune rejections. However, our recent studies have found that even syn- geneic iPSC-derived cells can be immunogenic in syn- geneic hosts by using a teratoma transplantation model （Nature 474：212-215, 2011）. Recently two research groups differentiated the iPSCs into different germ lay- ers or cells, transplanted those cells to the syngeneic hosts, and evaluated the immunogenicity of those cells. Both of the two studies support our conclusions that some certain but not all tissues derived from iPSCs can be immunogenic, although they claimed either ＂negli- gible＂ or ＂lack of＂ immunogenicity in iPSC derivatives （Nature 494：100-104, 2013; Cell Stem Cell 12：407-412, 2013）. To test the immunogenicity of clinically valuable cells differentiated from human iPSCs are emergenUy required for translation of iPSC technology to clinics.
11-5886/Q
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1674-800X
1674-8018
1674-8018
DOI:10.1007/s13238-013-0003-2